Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) surged in pre-market trading after the company reported the FDA approval of OGSIVEO (nirogacestat) as the first and only treatment for adults with desmoid tumors.
SpringWorks Therapeutics shares rose 14.4% to $23.77 in pre-market trading
Here are some other stocks moving in pre-market trading.
Gainers
Losers
Now Read This: Intuit, NetApp And 3 Stocks To Watch Heading Into Tuesday
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
